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Abstract
Objective: In adults with hyperinsulinaemic hypoglycaemia (HH), in particular those with 
insulinoma, the optimal diagnostic and management strategies remain uncertain. Here, 
we sought to characterise the biochemical and radiological assessment, and clinical 
management of adults with HH at a tertiary centre over a thirteen-year period.
Design: Clinical, biochemical, radiological and histological data were reviewed from all 
confirmed cases of adult-onset hyperinsulinaemic hypoglycaemia at our centre between 
2003 and 2016. In a subset of patients with stage I insulinoma, whole-exome sequencing 
of tumour DNA was performed.
Results: Twenty-nine patients were identified (27 insulinoma, including 6 subjects with 
metastatic disease; 1 pro-insulin/GLP-1 co-secreting tumour; 1 activating glucokinase 
mutation). In all cases, hypoglycaemia (glucose ≤2.2 mmol/L) was achieved within 48 h of 
a supervised fast. At fast termination, subjects with stage IV insulinoma had significantly 
higher insulin, C-peptide and pro-insulin compared to those with insulinoma staged  
I–IIIB. Preoperative localisation of insulinoma was most successfully achieved with EUS. 
In two patients with inoperable, metastatic insulinoma, peptide receptor radionuclide 
therapy (PRRT) with 177Lu-DOTATATE rapidly restored euglycaemia and lowered fasting 
insulin. Finally, in a subset of stage I insulinoma, whole-exome sequencing of tumour 
DNA identified the pathogenic Ying Yang-1 (YY1) somatic mutation (c.C1115G/p.T372R) 
in one tumour, with all tumours exhibiting a low somatic mutation burden.
Conclusion: Our study highlights, in particular, the utility of the 48-h fast in the diagnosis 
of insulinoma, EUS for tumour localisation and the value of PRRT therapy in the treatment 
of metastatic disease.
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Abstract
Objective: In adults with hyperinsulinaemic hypoglycaemia (HH), in particular those with 
insulinoma, the optimal diagnostic and management strategies remain uncertain. Here, 
we sought to characterise the biochemical and radiological assessment, and clinical 
management of adults with HH at a tertiary centre over a thirteen-year period.
Design: Clinical, biochemical, radiological and histological data were reviewed from all 
confirmed cases of adult-onset hyperinsulinaemic hypoglycaemia at our centre between 
2003 and 2016. In a subset of patients with stage I insulinoma, whole-exome sequencing 
of tumour DNA was performed.
Results: Twenty-nine patients were identified (27 insulinoma, including 6 subjects with 
metastatic disease; 1 pro-insulin/GLP-1 co-secreting tumour; 1 activating glucokinase 
mutation). In all cases, hypoglycaemia (glucose ≤2.2 mmol/L) was achieved within 48 h of 
a supervised fast. At fast termination, subjects with stage IV insulinoma had significantly 
higher insulin, C-peptide and pro-insulin compared to those with insulinoma staged  
I–IIIB. Preoperative localisation of insulinoma was most successfully achieved with EUS. 
In two patients with inoperable, metastatic insulinoma, peptide receptor radionuclide 
therapy (PRRT) with 177Lu-DOTATATE rapidly restored euglycaemia and lowered fasting 
insulin. Finally, in a subset of stage I insulinoma, whole-exome sequencing of tumour 
DNA identified the pathogenic Ying Yang-1 (YY1) somatic mutation (c.C1115G/p.T372R) 
in one tumour, with all tumours exhibiting a low somatic mutation burden.
Conclusion: Our study highlights, in particular, the utility of the 48-h fast in the diagnosis 
of insulinoma, EUS for tumour localisation and the value of PRRT therapy in the treatment 
of metastatic disease.
Introduction
Hyperinsulinaemic hypoglycaemia (HH) is uncommon in 
otherwise healthy adults due to the existence of robust 
counter-regulatory homeostatic mechanisms that defend 
against falling blood glucose concentrations. A clinical 
diagnosis of HH based on reported symptoms alone 
is challenging due to their lack of specificity and the 
attenuation of physiological responses with protracted 
hypoglycaemia. Whipple’s triad states that symptoms 
compatible with hypoglycaemia occur concomitantly with 
a low plasma glucose concentration and are ameliorated 
following restoration of euglycaemia. It is recommended 
that only once these criteria are satisfied should further 
investigations be embarked upon to determine the 
aetiology of the hypoglycaemic disorder (1).
Rare non-genetic and genetic causes of adult-onset 
HH have been described, the most common being benign 
insulinoma. These are insulin-secreting tumours of the 
pancreatic islets with an annual incidence 1–2 per million 
population, and associated with multiple endocrine 
neoplasia (MEN)-1 (1). Although single-copy deletion 
and somatic mutations in Menin have been identified 
in some sporadic insulinoma, it is now recognised that 
a recurrent somatic mutation in the transcription factor 
Ying Yang 1 (YY1T372R) occurs in up to one-third of 
tumours (2). However, for the majority of insulinoma, the 
underlying genetic event(s) that promote tumourigenesis 
remain unknown.
Consensus guidelines recommend a supervised fast 
of up to 72 h as a practical approach for provoking and 
establishing a diagnosis of spontaneous hypoglycaemia 
(1, 3). However, given the pressures on inpatient hospital 
bed capacity and the unpleasantness of a prolonged fast, 
alternative strategies that are both clinically effective and 
time-effective warrant consideration. Surgical resection of 
an insulinoma will be curative for most patients. However, 
this may be limited by difficulty in successful tumour 
localisation as the majority of insulinoma are small and 
often elusive on conventional cross-sectional imaging. 
Moreover, detection rates for insulinoma with commonly 
used non-invasive and invasive imaging modalities vary 
markedly, and currently no consensus exists regarding 
optimal imaging strategies.
In patients with metastatic disease and intractable 
hypoglycaemia, maintenance of euglycaemia, progression-
free survival and, importantly, preservation of quality 
of life form the basis of clinical management. These 
objectives are not often realised with supplementary 
carbohydrates alone. Refractory hypoglycaemia may 
be successfully treated with adjunctive therapeutics 
including diazoxide, somatostatin analogues or 
mammalian target of rapamycin (mTOR) inhibitors (4, 5). 
Although these therapies demonstrate clinical efficacy in 
some patients, intolerable side-effects often render them 
unsuitable for others. Furthermore, the low incidence 
of metastatic insulinoma precludes comparison of the 
clinical efficacy of these therapies in adequately powered, 
controlled clinical trials. Thus, reporting outcomes from 
patient series remains a vital conduit for disseminating 
evidence that additional therapies may be used safely and 
effectively to manage refractory hypoglycaemia in this 
rare and clinically challenging patient group.
We present a retrospective analysis of adult patients 
with biochemically confirmed HH to characterise 
their biochemical, radiological assessment and clinical 
management. Furthermore, we report two cases of 
inoperable malignant insulinoma with severe refractory 
hypoglycaemia, in whom PRRT with [177Lu]-octreotate 
successfully controlled hypoglycaemia. Finally, in a 
subset of stage I insulinoma, whole-exome sequencing 
of tumour DNA was performed, aiming to identify 
somatic mutations involved in tumour development and 
autonomous insulin secretion.
Patients and methods
Study population
We retrospectively reviewed medical records of patients 
presenting to our institution between 2003 and 2016 with a 
diagnosis of hyperinsulinaemic hypoglycaemia, confirmed 
biochemically during a supervised inpatient fast of up 
to 72 h. Serum blood glucose was measured every 4–6 h, 
with a laboratory-assayed plasma glucose of ≤2.2 mmol/L 
used as the biochemical criterion for fast termination. 
Notably, in some instances, fasts were terminated despite 
an absence of neuroglycopenic symptoms, providing 
the biochemical plasma glucose threshold was achieved. 
At the time of fast termination, blood was taken for 
measurement of insulin and, in most cases, pro-insulin 
and C-peptide. A sulfonylurea screen was also performed. 
We included patients known to have inherited tumour 
syndromes, such as MEN-1. We did not include patients 
with a history of bariatric surgery or with a negative 72-h 
fast followed by a negative plasma glucose response to 
intravenous glucagon. We also excluded patients with a 
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negative 72-h fast who exhibited biochemical evidence of 
reactive hypoglycaemia following either a prolonged (5-h) 
oral glucose tolerance or mixed-meal test. We collected 
data related to demographics, clinical history, relevant 
biochemical and radiological investigations, management, 
histopathology and follow-up. Tumour staging was 
reported in accordance with European Tumour Society 
(ENETS) consensus guidelines (6). Clinical and genetic 
studies were performed after approval of the National 
Health Service Research Ethics Committee United 
Kingdom. Each participant provided written informed 
consent, and all studies were conducted in accordance 
with the principles of the Declaration of Helsinki.
Analytic methods
The assays for measurement of insulin, C-peptide and pro-
insulin have been previously described (7).
Genomic DNA isolation and whole-exome sequencing
Genomic DNA extraction from both blood and benign 
insulinoma samples was performed using the QIAamp 
DNA Mini Kit (Qiagen) in accordance with manufacturer’s 
instructions. Genomic DNA was quantified using 
QuantiFluor dsDNA System (Promega) and 50 ng of 
DNA from each sample was used to generate barcoded 
whole-exome sequencing (WES) libraries according to 
manufacturer’s protocols (Illumina Nextera Rapid Capture 
Exome Kit, San Diego, CA, USA). WES libraries were 
quantified by QPCR (KAPA Biosystems, Wilmington, MA, 
USA) and equal concentrations (10 nM) of each library 
were pooled and subjected to one lane of paired-end 
125 bp sequencing on an Illumina HiSeq 2500 System.
Bioinformatics
WES yielded an average of 19.5 M read pairs per sample 
and the sequence reads were aligned to the Human 
UCSC hg38 genome using BWA, version 0.7.5 with 
an average mapping rate of 99.7%. The aligned reads 
were then subjected to pre-processing using Picard 
(version 1.127) and GATK (version 3.30) to correct for 
duplicate reads, mapping and sequencing artefacts in 
accordance with GATK best practice guidance (https://
software.broadinstitute.org/gatk/best-practices). Somatic 
variants were identified using Mutect (version 1.1.7) and 
annotated using Variant Effect Predictor (version 83, 
dbNSFP version 3.1a). Ta
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Results
Characteristics of study population
Twenty-nine patients (21 females, 8 males; mean age 52.6, 
range 16–88  years), with HH were identified (Table  1). 
Histopathological analysis confirmed that 27 cases were 
due to insulinoma (stage I (n = 12); stage IIA (n = 5); stage 
IIB (n = 1); stage IIIB (n = 3); stage IV (n = 3)). Of these, 3 
insulinoma (stage IIA (n = 2); stage IIIB (n = 1)) occurred 
in the context of MEN-1. We also identified one case of 
a pro-insulin/GLP-1-secreting tumour and one patient 
with an activating glucokinase mutation presenting for 
the first time in adulthood. Details of these two latter 
cases have been described (7, 8). Among the 27 patients 
with insulinoma, 26 patients reported hypoglycaemic 
symptoms in the fasting state, whereas 1 patient reported 
post-prandial symptoms.
Diagnostic testing
In all patients, a supervised inpatient fast of up to 72 h was 
performed to confirm HH. A laboratory-assayed plasma 
glucose of ≤2.2 mmol/L was the biochemical criterion 
for fast termination. Of 24 patients with insulinoma for 
whom fast duration data were available, 19 fasts were 
terminated within 24 h, and 5 fasts were terminated 
between 24 and 48 h (Table 1). Notably, the patient who 
reported post-prandial symptoms had a positive fast 
terminated after just seven hours. Among patients with 
stage IV insulinoma, all fasts were terminated within 
24 h. For comparison, and as reported previously, among 
subjects in our cohort with non-insulinoma-mediated 
hyperinsulinism, hypoglycaemia was provoked following 
four hours of fasting in the patient with a pro-insulin/
GLP-1 co-secreting tumour (8), whereas 34 h of fasting 
was required to achieve the biochemical criteria for 
fast termination in the context of an activating GCK 
mutation (7).
Among patients with insulinoma without distant 
metastases (n = 24), mean insulin concentration (stage  I: 
71 pmol/L (range 18–210); stage IIA/IIB: 97 pmol/L 
(range 21–240); stage IIIB: 90 pmol/L (range 63–117)) 
was significantly less than patients with stage 4 disease 
(405 pmol/L (range 133–555)) (P < 0.001) (Fig.  1 and 
Table 1) at the time of fast termination. Similarly, mean 
C-peptide concentration was also significantly lower in the 
absence of distant metastases (stage I: 1249 pmol/L (range 
294–1820); stage IIA/IIB: 709 pmol/L (range 387–1686); 
stage IIIB: 1011 pmol/L (range 842–1077)) compared 
Figure 1
Biochemistry (insulin, C-peptide) at fast termination (plasma glucose 
<2.2 mmol/L) and presenting HbA1c in patients with stage I, IIA/IIB, IIIB 
and IV insulinoma.
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with stage IV disease (2101 pmol/L (range 913–2991)) 
(P < 0.01). There was no statistical difference in HbA1c 
at presentation between groups (stage 1: 29.8 mmol/mol 
(range 22–36); stage IIA/IIB: 25 mmol/mol (range 17–29); 
stage IIIB: 33 mmol/mol); stage IV: 28 mmol/mol (range 
23–31)). For comparison, similar biochemical parameters 
are presented for patients with the pro-insulin/GLP-1 
co-secreting tumour and activating glucokinase mutation 
(Fig. 1 and Table 1).
Radiological localisation of insulinoma
Radiological localisation data are summarised (Fig.  2). 
Among patients with insulinoma, computed tomography 
(CT) was the initial imaging modality used in 22 cases. Of 
these, CT successfully detected the tumour in 15 cases and 
failed to localise 7 tumours (sensitivity, 68%). Magnetic 
resonance imaging (MRI) correctly detected 5 out of 9 
insulinoma (sensitivity, 56%). Of the four tumours not 
detected, three were also not localised by CT. CT was 
not performed in the fourth case. Overall, cross-sectional 
imaging (CT or MRI) detected stage I–IIIB insulinoma in 
21 of 24 subjects.
Over the period covered by this retrospective analysis, 
the preferred invasive preoperative localisation modalities 
in our centre shifted from pancreatic angiography and 
intra-arterial calcium stimulation with hepatic vein 
catheterisation to endoscopic ultrasound (EUS). When 
used, angiography regionalised 5 of 8 lesions, and 
when used for a single patient, selective arterial calcium 
stimulation successfully localised the tumour. Among 22 
patients who underwent EUS, insulinoma was correctly 
detected in 21 cases (sensitivity, 95%). Moreover, EUS 
was correctly detected insulinoma in 5 of 6 cases where 
a tumour was not identified by cross-sectional imaging. 
Notably, in 3 cases of MEN1-related insulinoma, 
background microadenomatosis was also visualised 
by EUS. In the single case where EUS was unsuccessful, 
calcium stimulation regionalised the tumour to the 
pancreatic tail.
Clinical management of insulinoma
Medical management of HH In addition to regular 
carbohydrate-based meals and snacks, 28 out of 29 patients 
required at least one additional supportive therapy 
to manage hypoglycaemia (individual carbohydrate 
requirements 1 g CHO/kg every 4–6 h (9) and 0.2–0.25 g 
glucose/kg/h to compensate for endogenous glucose 
production (10)). Dietary complex carbohydrate (corn 
starch) was the most commonly used adjunct (19 out of 
29 patients). Diazoxide was initiated in 14 patients, with 
dose and scheduling regimes (50 mg once daily to 150 mg 
three times daily) determined by clinical efficacy and 
tolerability. Of these, five subjects required concomitant 
corn starch to maintain euglycaemia. Somatostatin 
analogue treatment was reserved for patients with 
octreotide-avid metastatic disease (stage IV insulinoma 
(n = 3); metastatic GLP-1/pro-insulin-secreting pNET 
(n = 1). Of these, 1 patient with the GLP-1/pro-insulin-
secreting pNET died during the treatment course, whilst 
a second patient with metastatic insulinoma commenced 
concomitant systemic chemotherapy (streptozocin and 
capecitabine). This patient died shortly after treatment 
initiation. Two patients with malignant insulinoma 
proceeded to PRRT with [177Lu]-octreotate following 
conventional medical management and attempted trans-
arterial embolisation (TAE) of hepatic metastases due to 
refractory hypoglycaemia (detailed below).
PRRT in patients with malignant 
insulinoma Case  1: A 32-year-old female presented 
following severe hypoglycaemia and neuroglycopenic 
symptoms during labour. HH was confirmed (fasting 
glucose 0.6 mmol/L, insulin 555 pmol/L, C-peptide 
2406 pmol/L). Abdominal CT demonstrated a mass within 
the pancreatic tail (83 mm × 53 mm) and multiple hepatic 
metastases. [111In]-pentetreotide scanning demonstrated 
avidity throughout the liver, pancreatic tail, left groin, 
right humeral head and left cervical region (Fig.  3A). 
Figure 2
Radiological modalities used to localise benign insulinoma. Black bars 
indicate number of cases examined with each technique; White bars 
indicate number of successfully localised insulinoma.
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Histology of a biopsied liver metastasis revealed a grade 
1 well-differentiated pancreatic neuroendocrine tumour 
(Ki-67 5%).
Severe hypoglycaemia persisted despite treatment 
with intravenous 20% dextrose, corn starch and diazoxide 
(100 mg tds). Similarly, TAE of hepatic metastases did not 
control hypoglycaemia. Lanreotide (120 mg every 28 days) 
was commenced, resulting in less frequent hypoglycaemia. 
The patient was subsequently treated with four cycles 
of [177Lu]-DOTATATE, at 12-week intervals, up to a 
total administered activity of 29.6 GBq. Hypoglycaemia 
was immediately abolished following the first cycle of 
[177Lu]-DOTATATE. After four cycles, hypoglycaemia 
remained well controlled, with a significant reduction 
in peak fasting insulin (31 pmol/L) (Fig.  3B). No renal 
toxicities were detected; however, pancytopenia developed 
following the fourth cycle requiring granulocyte-colony-
stimulating factor and has been slow to improve. To date, 
16 months following the first cycle of [177Lu]-DOTATATE, 
radiological surveillance demonstrates reduction in size 
of the primary tumour and some liver metastases, with 
maintenance of normoglycaemia on normal diet alone.
Case 2: A 32-year-old female presented with slurred 
speech and confusion associated with minimal exertion and 
missed meals. During a supervised fast, HH was confirmed 
(glucose 1.4 mmol/L, insulin 122 pmol/L, pro-insulin 
>200 pmol/L and C-peptide 1220 pmol/L). Abdominal CT 
demonstrated a 9 mm lesion in the pancreatic body and 
multiple liver metastases. [111In]-pentetreotide scanning 
failed to demonstrate avidity in the pancreatic mass or liver 
lesions, whereas 68Ga-DOTATE PET-CT revealed moderate 
avidity in the hepatic lesions and para-aortic lymph nodes. 
EUS-guided fine needle aspiration of the pancreatic mass, 
and cytological examination, revealed a well-differentiated 
grade 1 neuroendocrine tumour (Ki-67–5%).
Maintenance of euglycaemia required continuous 
intravenous dextrose (20%), regular meals (including 
throughout the night) and corn starch. Diazoxide (100 mg 
tds) was stopped due to symptomatic tachycardia. 
TAE of the largest hepatic metastasis failed to reduce 
hypoglycaemic episodes. [177Lu]-DOTATATE treatment 
was commenced. After just one treatment cycle, 
hypoglycaemia was abolished and glucose levels remain 
well controlled with a normal diet and lanreotide (120 mg 
every 28 days). One month following [177Lu]-DOTATATE, 
overnight fasting plasma glucose levels were normal 
(5.5 mmol/L; insulin 59 pmol/L).
Surgical management of insulinoma Of 24 
patients with suspected localised insulinoma, three either 
refused surgery or were deemed unfit; these were managed 
with supportive medical therapies alone. Twenty-one 
patients underwent surgery, and hypoglycaemia was 
cured in all cases (laparoscopic distal pancreatecomy; 
n = 12; Whipple’s procedure; n = 7; intraoperative 
enucleation; n = 2).
Follow-up of insulinoma patients Post-operatively, 
patients with stage I–IIIB insulinoma were assessed 
clinically and biochemically (HbA1c and/or fasting 
glucose) at 3, 6 and 12 months, and annually thereafter. 
Among 20 patients for whom post-operative follow-up 
data were available, there were no episodes of disease 
recurrence (median follow-up: 56 months; range: 4–161). 
Similarly, patients with MEN-1 (n = 3) were surveyed in 
accordance with published consensus guidelines (11), 
with no evidence of insulinoma recurrence (median 
follow-up: 75 months; range: 66–150).
Figure 3
(A) Representative Octreoscan image. (B) Fasting 
plasma insulin concentrations (pmol/L) in a 
patient with metastatic (stage IV) insulinoma 
following treatment with 177Lu-Dotatate (PRRT).
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Insulinoma characteristics
Of the surgically resected insulinoma, 3 tumours were 
identified within the pancreatic head, 3 in the uncinate 
process, 8 in the body and 7 in the pancreatic tail. Mean 
tumour diameter was 15.7 mm (range 6–45). Sixteen 
tumours were less than 2 cm in diameter, 5 less than 
2–4 cm and 1 was greater than 4 cm. In accordance with 
the ENETS classification (6), tumour staging is shown in 
Supplementary Table 1 (see section on supplementary 
data given at the end of this article).
Whole-exome sequencing of benign insulinoma
Four pairs of DNA extracted from stage I insulinoma and 
matched blood lymphocytes were selected for WES. The 
average sequencing depth was 130-fold (111–146), and 
97% (95.6–97.5%) of the target regions were covered 
at least 30-fold. Using a coverage cut-off of at least 
30-fold, we identified 101 somatic mutations among 
the 4 tumour exomes (Supplementary Fig.  1), affecting 
178 unique genes and 701 coding transcripts. These 
included 30 synonymous, 61 missense and four nonsense 
mutations, and 1 splice site mutation within the coding 
region (Supplementary Fig.  1). Supplementary Table 2 
includes somatic mutations predicted to have damaging 
consequences to gene function, as determined by the 
in silico prediction tools, SIFT and PolyPhen. The 
previously reported recurrent somatic mutation in YY1 
(c.C1115G/p.T372R) was identified in 1 insulinoma and 
confirmed by Sanger sequencing (data not shown).
Discussion
In our study, all patients who underwent investigation 
for hypoglycaemia, and were subsequently diagnosed 
with insulinoma, had a positive fast within 48 h. This 
is consistent with other such series, where positive fasts 
were reported within 48 h for >93% of cases (3, 12). 
Hirshberg and coworkers identified 119 patients with 
insulinoma; 94.5% had their fasts terminated within 48 h 
when hypoglycaemia (plasma glucose <2.2 mmol/L) was 
accompanied by neuroglycopenic symptoms (12). Of 
those in whom fasting was extended beyond 48 h, all had 
biochemical HH before 48 h; the fasts were continued 
because patients did not yet exhibit neuroglycopenic 
symptoms. In our series, fast termination was based 
on robust biochemical criteria alone without the 
requirement for co-existing neuroglycopenic symptoms. 
Although discordant with current guidance, and of 
smaller sample size compared with published studies, our 
data suggest that a 48-h fast is effective at identifying the 
majority of patients who require further investigation, 
avoiding unnecessarily prolonged fasts in asymptomatic 
subjects who otherwise exhibit diagnostic biochemistry. 
Indeed, given that patients with insulinoma may 
exhibit impaired awareness of hypoglycaemia due to an 
attenuated sympathoadrenal response following exposure 
to prolonged antecedent hypoglycaemia, emphasis on 
the presence of neuroglycopenic symptoms may be 
unnecessary (13). Notably, however, negative 72-h fasts 
have rarely been reported in insulinoma patients (14), 
and clinical judgement remains imperative to avoid 
misdiagnosis. Similarly, rare causes of non-insulinoma-
mediated hypoglycaemia, such as activating glucokinase 
mutations, may give rise to a negative 72-h fast (15). 
In such rare cases, however, a suggestive family history 
and/or stability of hypoglycaemia throughout a fast are 
important diagnostic clues.
The small size of most benign insulinoma makes 
radiological localisation challenging, but this is critical 
for minimising operating times and improving surgical 
outcome (16). Conventional non-invasive imaging 
techniques such as CT or MRI are first-line investigations due 
to their availability and safety. However, they are inferior 
to invasive procedures for localising small insulinoma 
(16, 17). Intra-arterial calcium stimulation and EUS have 
repeatedly been shown to have higher detection rates than 
non-invasive methods (80–90% and 75–93% sensitivity, 
respectively) (16, 17, 18). In our series, the detection rate 
of insulinoma by EUS was 95% compared with 78% for CT 
and MRI. Limitations of EUS include availability, operator- 
and centre-dependence, invasiveness and reduced ability 
to detect lesions within the pancreatic tail. Indeed, the 
single insulinoma in our series not detected by EUS was 
subsequently regionalised to the pancreatic tail by intra-
arterial calcium stimulation. An additional benefit of EUS, 
however, is the ability to undertake biopsies of pancreatic 
lesions alongside visualisation, thereby confirming 
diagnosis of a pNET in  situ. Moreover, EUS facilitates 
ablation of pNETs, including insulinoma, for those patients 
in whom surgery may pose significant risks (19, 20, 21). 
Whilst numbers of patients undergoing these procedures 
remain small, short-term follow-up data and complication 
rate are encouraging.
Surgical resection with curative intent is standard 
of care for benign insulinoma. In cases of metastatic 
disease, refractory hypoglycaemia presents a clinical 
challenge, contributing to the increased morbidity 
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and mortality observed for these patients. Therapeutic 
options for refractory hypoglycaemia include diazoxide, 
somatostatin analogues, mTOR inhibitors and PRRT. 
Diazoxide is the most commonly used therapy for 
refractory hypoglycaemia but has limited efficacy at 
tolerated doses with recognised adverse effects at higher 
doses. Similarly, traditional somatostatin analogues (SSA), 
which demonstrate high affinity for SSTR2 and SSTR5 
receptor subtypes, have variable utility, likely reflecting 
differential expression of somatostatin receptor subtypes 
among insulinoma (4). Paradoxically, SSA may transiently 
potentiate hypoglycaemia due to suppression of counter-
regulatory hormones (22). Abolition of hypoglycaemia 
and tumour regression has been reported with everolimus 
(5, 23) and this agent is recommended for use in malignant 
insulinoma resistant to standard medical therapy 
(24). Adverse effects are common, however, including 
immunosuppression, myelotoxicity, pneumonitis and 
cardiac dysfunction (23).
PRRT, using 111In-, 177Lu- or 90Yt-labelled somatostatin 
analogues, is widely used for treatment of metastatic 
neuroendocrine tumours expressing somatostatin 
receptors (4, 25). In the cases we describe, hypoglycaemia 
was stabilised within hours of 177Lu-octreotate therapy 
and, in one instance, remains controlled 16  months 
following PRRT with normal diet and ongoing lanreotide. 
Other investigators have also reported rapid abolition of 
hypoglycaemia following PRRT in malignant insulinoma 
(4, 25). Thus, for patients reliant on inpatient support 
for maintenance of euglycaemia (e.g., with intravenous 
glucose) PRRT may provide a clinically efficacious option 
permitting outpatient management and, importantly, 
improved quality of life. In addition to the metabolic 
benefits of PRRT, our patients had stable disease 
radiologically post-PRRT. Whilst our patients were treated 
only recently, that PRRT has anti-proliferative effects in 
malignant insulinoma is supported by reports of delayed 
disease progression of up to 50 months following PRRT 
(25). Whether PRRT has superior anti-proliferative 
benefits compared with other currently available systemic 
therapies, however, remains unclear and given the rarity 
of malignant insulinoma this question is unlikely to be 
answered in a sufficiently powered clinical trial.
Through WES of tumour DNA, we and others 
demonstrate that benign and malignant insulinoma have 
a low frequency of non-synonymous somatic mutations 
(2, 26, 27). This has important clinical relevance, 
suggesting that immunotherapies targeting checkpoint 
molecules, such as CTLA-4 or PD-1 are unlikely to yield 
significant clinical benefit in metastatic insulinoma. 
Mechanistically, these agents exhibit their anti-tumour 
effects by enhancing activity of endogenous T cells against 
cancerous cells and are most clinically efficacious against 
tumour types with high non-synomymous mutation 
frequencies and large neoantigen repetoires (28).
For the majority of insulinoma, the molecular 
events underlying tumour development remain unclear. 
Indeed, published studies for WES in insulinoma 
demonstrate minimal overlap between genes containing 
protein-altering mutations (data not shown). We did 
not identify somatic mutations in genes previously 
implicated in development of pancreatic neuroendocrine 
tumours, including Menin, DAXX or ATRX (29). We 
did, however, identify a somatic missense mutation in 
the transcription factor YY1 (YY1T372R) in one benign 
insulinoma, consistent with previous studies which 
found YY1T372R to occur in up to one-third of such cases 
(2). Recently, Cromer and coworkers demonstrated that 
T372R is a neomorphic mutation that alters the DNA 
binding specificity of YY1 resulting in marked changes 
in target gene expression, culminating in autonomous 
insulin secretion and tumourigenesis (27). Other than 
the possibility of female preponderance, insulinoma 
harbouring YY1T372R do not appear to differ clinically 
from wild-type tumours (26, 27).
In conclusion, our report adds to the existing 
literature informing clinical practice for the management 
of hyperinsulinaemic hypoglycaemia. In particular, our 
data highlights the validity of a 48-h fast for biochemical 
diagnosis in suspected insulinoma, and the use of EUS in 
conjunction with cross-sectional imaging for localisation 
of insulinoma in order to facilitate curative surgery. 
Finally, we provide evidence for the utility of PRRT in the 
management of malignant disease.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
EC-17-0076.
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